HRTX shows a gain of about 31% in the supplied Penny Gems screenshots. The strongest verified news behind the attention is Heron Therapeutics’ November 9 agreement to sell substantially all its assets to CorMedix, alongside quarterly results showing lower revenue.
The snapshot shows a jump within a longer decline
The leading six-month chart shows $0.39 after rounding to the nearest cent, a +31.28% gain and 112.85 million shares traded. A separate details screen shows 31.54% and 112.87 million shares. These are separate app readings, not a verified closing quote.
The screenshots show device times of 7:21–7:22 without a time zone or full capture date. Their news headlines match November 9 disclosures. The longer charts still show a pronounced decline, while the one-month view ends with a sharp rebound. A single strong session cannot establish a durable reversal.
The proposed sale changes what HRTX represents
CorMedix agreed to pay $145 million in cash, subject to adjustments, and issue 14.58 million shares. The company valued that stock at $77.60 million using its November 6 closing price, making upfront consideration approximately $222.60 million. The share count is fixed, so its value can change. Closing is expected in the first quarter of 2027, subject to shareholder approval, regulatory clearance and other conditions. [Transaction announcement](https://ir.herontx.com/news-releases/news-release-details/cormedix-therapeutics-acquire-substantially-all-assets-heron).
Sale proceeds are not a direct shareholder payout
Heron plans to remain public rather than liquidate. It intends to repay its credit facility and evaluate investments or acquisitions. Cash and stock consideration are payable to Heron, not automatically distributed to HRTX shareholders. Separate arrangements also use CorMedix shares to settle convertible debt. [Heron filing](https://www.sec.gov/Archives/edgar/data/818033/000119312526452672/hrtx-20261108.htm).
An asset-sale headline therefore cannot be divided by the share count and presented as a guaranteed payout. Debt, retained obligations, transaction adjustments and future board decisions matter.
Earnings explain why the transaction matters
Third-quarter revenue was $35.25 million, down −7.80% year over year. Acute-care growth did not offset oncology weakness. Cash, equivalents and short-term investments totaled $23.40 million at quarter-end. SUSTOL commercial sales stopped September 30, and the company is not providing annual guidance. The profile text in the screenshots should not override these newer disclosures. [Quarterly results](https://www.sec.gov/Archives/edgar/data/818033/000119312526452721/hrtx-ex99_1.htm).
What to watch before calling this a turnaround
The next tests are approval and closing, debt settlement, the value of the CorMedix shares and Heron’s eventual use of the remaining assets. Contingent payments are potential upside, not cash already earned. The deal offers a concrete explanation for renewed attention, while the exact motives behind individual trades remain unverified.
Heavy turnover also needs context. Volume counts shares changing hands, not unique investors, and the same shares can trade repeatedly. Without a comparable average-volume baseline or evidence of positioning, the screenshots alone cannot establish institutional buying or a short squeeze.
This is market reporting, not a recommendation to buy or sell. HOLD is an app label, not this article’s advice.
